Prerana Bhan, Director of Business Development and Strategic Division at ACT Genomics, shared a post on LinkedIn:
“Reminiscing my time at ESMO ASIA 2025
Grateful for the meaningful conversations, scientific exchange, and connections that made this experience truly memorable. From discussions on biomarkers and liquid biopsy to regional collaboration across APAC, ESMO once again reinforced why we do what we do in precision oncology.
Several real and recurring themes include:
- Biomarker-driven treatment is no longer optional: expanding beyond EGFR/ALK into HRD, ESR1, FGFR, IDH, and resistance mechanisms
- Liquid biopsy adoption is accelerating, particularly for treatment selection and monitoring, though reimbursement and awareness gaps remain in many Asian markets
- Asia-centric clinical trials and real-world evidence are becoming critical, with Pharma actively seeking regional genomic data and testing partners
- Decentralized and local testing models are increasingly favored to support faster TATs, regulatory alignment, and scalable trial execution
- A clear push toward integrated diagnostics plus data plus clinical strategy, rather than standalone testing
At ACT Genomics, these discussions reaffirm our focus on:
- Comprehensive NGS solutions across tissue and liquid
- CAP-accredited clinical and research services
- Strong APAC presence and regulatory familiarity
- Flexible collaboration models for Pharma and CRO partners
Thank you to all the partners, collaborators, and peers who took the time to connect during ESMO Asia.
Looking forward to translating these conversations into meaningful partnerships and impact across APAC in 2026.
For your reference, our poster information is available”
More posts about ESMO ASIA 2025.
